408 related articles for article (PubMed ID: 31195849)
1. Repositioning rifamycins for Mycobacterium abscessus lung disease.
Ganapathy US; Dartois V; Dick T
Expert Opin Drug Discov; 2019 Sep; 14(9):867-878. PubMed ID: 31195849
[No Abstract] [Full Text] [Related]
2. Rifabutin Is Active against Mycobacterium abscessus in Mice.
Dick T; Shin SJ; Koh WJ; Dartois V; Gengenbacher M
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767722
[TBL] [Abstract][Full Text] [Related]
3. Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.
Ganapathy US; Lan T; Krastel P; Lindman M; Zimmerman MD; Ho H; Sarathy JP; Evans JC; Dartois V; Aldrich CC; Dick T
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0097821. PubMed ID: 34228543
[TBL] [Abstract][Full Text] [Related]
4. Rifamycin O, An Alternative Anti-
Hanh BTB; Park JW; Kim TH; Kim JS; Yang CS; Jang K; Cui J; Oh DC; Jang J
Molecules; 2020 Mar; 25(7):. PubMed ID: 32244387
[No Abstract] [Full Text] [Related]
5. ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant
Xie M; Ganapathy US; Lan T; Osiecki P; Sarathy JP; Dartois V; Aldrich CC; Dick T
Antimicrob Agents Chemother; 2023 Sep; 67(9):e0038123. PubMed ID: 37493373
[TBL] [Abstract][Full Text] [Related]
6. Rifabutin Is Active against Mycobacterium abscessus Complex.
Aziz DB; Low JL; Wu ML; Gengenbacher M; Teo JWP; Dartois V; Dick T
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396540
[TBL] [Abstract][Full Text] [Related]
7. Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.
Johansen MD; Daher W; Roquet-Banères F; Raynaud C; Alcaraz M; Maurer FP; Kremer L
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816730
[No Abstract] [Full Text] [Related]
8. Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.
Ganapathy US; Lan T; Dartois V; Aldrich CC; Dick T
Microbiol Spectr; 2023 Sep; 11(5):e0190023. PubMed ID: 37681986
[TBL] [Abstract][Full Text] [Related]
9. Rifabutin Is Inactivated by Mycobacterium abscessus Arr.
Schäfle D; Selchow P; Borer B; Meuli M; Rominski A; Schulthess B; Sander P
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318008
[No Abstract] [Full Text] [Related]
10. In vitro activity of rifabutin against Mycobacterium abscessus, clinical isolates.
Chen J; Zhang H; Guo Q; He S; Xu L; Zhang Z; Ma J; Chu H
Clin Exp Pharmacol Physiol; 2022 Jul; 49(7):767-775. PubMed ID: 35531776
[TBL] [Abstract][Full Text] [Related]
11. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.
Johansen MD; Herrmann JL; Kremer L
Nat Rev Microbiol; 2020 Jul; 18(7):392-407. PubMed ID: 32086501
[TBL] [Abstract][Full Text] [Related]
12. Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.
Pryjma M; Burian J; Thompson CJ
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760147
[No Abstract] [Full Text] [Related]
13.
Mann L; Ganapathy US; Abdelaziz R; Lang M; Zimmerman MD; Dartois V; Dick T; Richter A
Microbiol Spectr; 2022 Dec; 10(6):e0276022. PubMed ID: 36377951
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
Rominski A; Roditscheff A; Selchow P; Böttger EC; Sander P
J Antimicrob Chemother; 2017 Feb; 72(2):376-384. PubMed ID: 27999011
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.
Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795
[TBL] [Abstract][Full Text] [Related]
16.
Cheng A; Tsai YT; Chang SY; Sun HY; Wu UI; Sheng WH; Chen YC; Chang SC
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670428
[TBL] [Abstract][Full Text] [Related]
17. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
18. Differential
Lee J; Ammerman N; Agarwal A; Naji M; Li SY; Nuermberger E
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168614
[TBL] [Abstract][Full Text] [Related]
19. Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus.
Wang S; Cai X; Yu W; Zeng S; Zhang J; Guo L; Gao Y; Lu Z; Hameed HMA; Fang C; Tian X; Yusuf B; Chhotaray C; Alam MDS; Zhang B; Ge H; Maslov DA; Cook GM; Peng J; Lin Y; Zhong N; Zhang G; Zhang T
Microbiol Spectr; 2022 Aug; 10(4):e0276321. PubMed ID: 35946941
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium abscessus HelR interacts with RNA polymerase to confer intrinsic rifamycin resistance.
Hurst-Hess KR; Saxena A; Rudra P; Yang Y; Ghosh P
Mol Cell; 2022 Sep; 82(17):3166-3177.e5. PubMed ID: 35905736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
